I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| macrophage | 13 studies | 31% ± 13% | |
| microglial cell | 6 studies | 28% ± 10% | |
| myeloid cell | 5 studies | 23% ± 2% | |
| plasmacytoid dendritic cell | 4 studies | 19% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| macrophage | 13 studies | 31% ± 13% | |
| microglial cell | 6 studies | 28% ± 10% | |
| myeloid cell | 5 studies | 23% ± 2% | |
| plasmacytoid dendritic cell | 4 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of CMKLR1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 2248.58 | 577 / 578 | 91% | 10.55 | 1049 / 1155 |
| breast | 95% | 1116.75 | 434 / 459 | 96% | 11.10 | 1071 / 1118 |
| thymus | 99% | 2127.62 | 647 / 653 | 89% | 6.57 | 541 / 605 |
| prostate | 95% | 941.16 | 232 / 245 | 89% | 5.23 | 449 / 502 |
| intestine | 98% | 1040.53 | 943 / 966 | 71% | 5.57 | 376 / 527 |
| kidney | 80% | 623.56 | 71 / 89 | 87% | 11.48 | 787 / 901 |
| uterus | 94% | 1472.89 | 159 / 170 | 70% | 6.45 | 320 / 459 |
| adrenal gland | 98% | 1259.55 | 254 / 258 | 63% | 4.82 | 146 / 230 |
| bladder | 95% | 868.81 | 20 / 21 | 64% | 6.31 | 325 / 504 |
| skin | 69% | 571.60 | 1241 / 1809 | 90% | 14.20 | 426 / 472 |
| esophagus | 70% | 650.69 | 1012 / 1445 | 69% | 3.82 | 126 / 183 |
| pancreas | 50% | 257.55 | 165 / 328 | 87% | 9.44 | 155 / 178 |
| stomach | 58% | 453.82 | 209 / 359 | 77% | 7.65 | 221 / 286 |
| brain | 21% | 109.72 | 551 / 2642 | 98% | 13.33 | 691 / 705 |
| ovary | 37% | 330.43 | 67 / 180 | 68% | 4.36 | 294 / 430 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 53.62 | 29 / 29 |
| blood vessel | 100% | 4420.09 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 100% | 6091.02 | 240 / 241 | 0% | 0 | 0 / 0 |
| adipose | 100% | 2051.08 | 1199 / 1204 | 0% | 0 | 0 / 0 |
| heart | 92% | 884.19 | 795 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 9.72 | 41 / 45 |
| liver | 31% | 180.54 | 70 / 226 | 60% | 3.45 | 244 / 406 |
| peripheral blood | 72% | 644.95 | 665 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 56% | 3.15 | 45 / 80 |
| muscle | 34% | 192.35 | 272 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006954 | Biological process | inflammatory response |
| GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
| GO_0032695 | Biological process | negative regulation of interleukin-12 production |
| GO_0006935 | Biological process | chemotaxis |
| GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
| GO_0010759 | Biological process | positive regulation of macrophage chemotaxis |
| GO_0006955 | Biological process | immune response |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0070098 | Biological process | chemokine-mediated signaling pathway |
| GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
| GO_0050848 | Biological process | regulation of calcium-mediated signaling |
| GO_0045600 | Biological process | positive regulation of fat cell differentiation |
| GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
| GO_0001501 | Biological process | skeletal system development |
| GO_0002430 | Biological process | complement receptor mediated signaling pathway |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0004930 | Molecular function | G protein-coupled receptor activity |
| GO_0097003 | Molecular function | adipokinetic hormone receptor activity |
| GO_0097004 | Molecular function | adipokinetic hormone binding |
| GO_0004875 | Molecular function | complement receptor activity |
| GO_0004950 | Molecular function | chemokine receptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CMKLR1 |
| Protein name | Chemerin-like receptor 1 (Chemokine-like receptor 1) Chemerin-like receptor 1 (Chemokine-like receptor 1) (G-protein coupled receptor ChemR23) (G-protein coupled receptor DEZ) |
| Synonyms | DEZ CHEMR23 |
| Description | FUNCTION: Receptor for the chemoattractant adipokine chemerin/RARRES2 and for the omega-3 fatty acid derived molecule resolvin E1. Interaction with RARRES2 initiates activation of G proteins G(i)/G(o) and beta-arrestin pathways inducing cellular responses via second messenger pathways such as intracellular calcium mobilization, phosphorylation of MAP kinases MAPK1/MAPK3 (ERK1/2), TYRO3, MAPK14/P38MAPK and PI3K leading to multifunctional effects, like reduction of immune responses, enhancing of adipogenesis and angionesis . Resolvin E1 down-regulates cytokine production in macrophages by reducing the activation of MAPK1/3 (ERK1/2) and NF-kappa-B. Positively regulates adipogenesis and adipocyte metabolism. .; FUNCTION: (Microbial infection) Acts as a coreceptor for several SIV strains (SIVMAC316, SIVMAC239, SIVMACL7E-FR and SIVSM62A), as well as a primary HIV-1 strain (92UG024-2). . |
| Accessions | F8VYN7 Q6LEE7 ENST00000412676.5 [Q99788-1] F8VSC8 ENST00000550402.6 [Q99788-1] ENST00000550573.5 ENST00000552995.5 [Q99788-2] Q99788 ENST00000312143.11 [Q99788-1] ENST00000549466.1 |
